Figure 1From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer Estimate of overall survival. Kaplan-Meier graph showing proportion surviving over time (solid line) with estimates of 95% confidence (dotted line).Back to article page